Venture Life Dividends - VLG

Venture Life Dividends - VLG

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type
Venture Life Group Plc VLG London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
2.60 4.11% 65.80 16:25:01
Open Price Low Price High Price Close Price Previous Close
63.20 63.20 65.80 65.80 63.20
more quote information »
Industry Sector

Venture Life VLG Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount

Top Dividend Posts

red ninja: Nice to see fund buying, presumably they've reconsidered their investment in VLG after the last trading update although of course funds are not infallible.
mach100: There seems to be some law that the shares I sell due to bad performance (like VLG ) bounce and the ones I keep burrow their way down to zero. Or else China State Intelligence is spying on my PF and passing the trades to those hoping to make money :p
tole: Coverage on TMF heroToday, Venture Life Group (LSE: VLG) shares go for 68p a pop. It's a penny stock I think could make me a lot of money as its transformation strategy clicks through the gears. Venture Life manufactures non-prescription healthcare products such as Dentyl mouthwashes, Procto-eze Plus haemorrhoid creams and Myco Clear fungal nail treatments.Acquisitions are a key part of the UK share's growth strategy and last January it made the transformative takeover of PharmaSource BV to boost its product ranges as well as worldwide distribution.Venture Life has also invested heavily to increase production at its Biokosmes facility in Northern Italy. Capacity here now stands at 250,000 units versus 130,000 previously.Encouragingly, the UK healthcare share has plenty of financial clout to keep investing in the business and pursuing its M&A agenda. Indeed, a £36m share placing at the end of last year gave it the strength to acquire women's health and diabetes product specialist BBI in June and a series of oncology support products from Helsinn Healthcare earlier this month.I'm confident this stock's aggressive approach to acquisitions could light a fire under long-term profits growth. But remember that an M&A-led growth strategy can be extremely risky. Meanwhile, problems like unexpected costs, underwhelming revenues, and paying over the odds for an asset can be common problems that ultimately damage shareholder returns.
rivaldo: VLG are forecast by Cenkos to make 4.6p adjusted EPS this year, rising to 6.21p EPS next year following the acquisitions already in place - and with hefty facilities to enable further large earnings-enhancing acquisitions. Cenkos note that this could bring in £2m additional EBITDA in 2021, or if no acquisitions this year, then a further £3m EBITDA next year. The key point here is that the core business is trading well and should pick up further, as highlighted by Cenkos: "The core business, defined as the business excluding sales of Dentyl to the Chinese partner and HSG, is expected to report 9% growth in H1/21E, which we view as a strong result given the ongoing pandemic. While the impact of COVID continued into H1/21, the company is encouraged by indications of a post-pandemic recovery in UK retail, which we expect to support growth in this core business." "At an adjusted level, we expect diluted EPS for FY21E to be 4.5p, up c19% versus our previous estimate of 3.8p. We forecast adjusted diluted EPS of 6.2p for FY22E, indicating growth of 37% YoY." Management should have been much more open about the decline in the exceptional HSG and Dentyl China categories. But that doesn't offset the fact that the core business is building nicely and has the potential to grow much faster both organically and via acquisition.
rivaldo: I completely agree with ST that VLG looks cheap at these levels and there's been a huge over-reaction. VLG are forecast to make 6.21p EPS next year after the acquisitions already completed, and including almost nothing for hand sanitiser and Dentyl China. That's a P/E of just 11.3 at 70p. Then there's further upside from additional acquisitions, and indeed from any further gains from sanitiser or from China.
sphere25: Interesting events here recently - unfortunate one for ST. Plenty of good calls from ST, but everyone gets a left field wallop now and again. That is the nature of the arena we participate in. Following the move down, intrigued to see how the market reacts to the write up from yesterday. The sell off was on massive volume at over 6 million. VLG has rarely traded that much. You can get the odd bouts of large shares being exchanged, but to get a sell off like that on very significant volume really shows the market voting with its feet and a real distrust in management. Normally the shares don't recover quickly when you get that kind of a thumbs down, but there can be some very short term overreactions that get bought back, up so just watching in to see if the buying does pick up to at least match that 6 million. VLG has currently traded just over 2 million and there are sellers in size drip feeding at 69.5p (edit and now 69.76p) at the moment, closing off that 70p mark. There are some rogue buys going through at full ask to try to encourage market participants to buy (see this alot when there are sellers in size at work). It looks like buying needs to pick up significantly from here to get a bounce or the strength today could get sold into. All imo DYOR
melody9999: Hew - I think that VLG might have reported the Chinese distributor issue earlier. But the hand gel is just market demand. Overall, with other product lines performing well, it is not clear to me that management should have put out an additional RNS before the TU. Having said that, given the share price reaction, it will certainly focus management's attention on the issue. Meanwhile I concur with ST that this is a buying opportunity
sev22: Here is Simon Thompson's latest column released last night: Venture Life: Investors overlook massive earnings upgrades. It’s not often that a company releases a trading update, analysts upgrade their current year EPS estimates by 19 per cent and introduce estimates that indicate 38 per cent EPS growth next year, and the share price sheds a third of its value. However, that is exactly what has happened to Aim-traded Venture Life (VLG:65p), a developer, manufacturer and distributor of products for the self-care markets. Clearly, investors have been spooked by news of materially lower sales of hand sanitising gels and sales of the company’s Dentyl products to its Chinese partner. In the first half of 2021, these two segments delivered £0.3m of combined revenue, down from £5.5m in the first half of 2020, which explains why Venture’s first half revenue declined from £16.8m to £13.8m. Please note the latter figure includes a £1.1m revenue contribution from the recent acquisition of BBI Healthcare, a highly profitable global market leading women's health and diabetes/energy management company. Excluding these revenue streams, Venture’s other legacy businesses performed well, delivering 9 per cent higher revenue of £12.4m in the six-month period. The shortfall prompted house broker to rein in its 2021 revenue estimate from £33m to £29.2m for Venture’s legacy businesses, before accounting for the contribution from this summer’s earnings enhancing acquisitions which has prompted earnings upgrades. Though that’s disappointing, it is in no way a disaster given that the same businesses posted revenue of £30.1m in 2020, so effectively their revenue could only decline by 3 per cent year on year. I am not sure that many investors selling out have grasped this fact. True, the overstocking of hand sanitising gel in retail channels (that resulted from panic buying last year) will take time to unwind, so the contribution from this opportunistic segment isn’t going to be anything like last year. However, analysts weren’t factoring much in the way of second half sales in any case. More importantly, Venture’s partner for Dentyl in China is still suffering from the effects of the Covid-19 lockdowns in 2020 on its offline business, so is not taking new stock at the rate anticipated when it entered the distribution agreement in 2020. With a debtor balance of less than £300,000 outstanding, below the provision made in last year’s accounts, Venture could terminate the distribution agreement, as it’s entitled to, and take its business elsewhere effectively at nil cost. Chief executive Jerry Randall confirmed that he is talking to other European based companies which have operations in China with a view to entering an agreement with them unless the current distributor fulfils its obligations. Mr Randall also points out that Venture’s order book (pre-acquisitions and excluding orders for the China partner) is higher year on year despite the lockdowns across many markets, and expects Venture to produce meaningful revenue and profit growth in 2021. Unfortunately, the lack of earnings guidance in last Friday’s trading update has left retail investors in the dark, which has exacerbated the share price fall. I can shed some light on the matter. Crunching the numbers House broker Cenkos Securities produced a detailed note for clients which included material earnings upgrades, even if investors have ignored them, or perhaps more likely are simply unaware of them. The broker expects BBI to produce annual gross profit of £6.1m on revenue of £10.5m in 2021, and has taken a seven-month contribution from this high margin (58 per cent) business in its 2021 forecast. Cenkos also expects the more recent acquisition of Helsin Healthcare’s oncology support products to deliver 2021 gross profit of £1.3m on sales of £2.5m, and has embedded a five-month contribution into its 2021 forecasts. Combined the two acquisitions add £6.74m to 2021 revenue which when added to Cenkos’ £29.2m reduced forecast for Venture’s legacy business means that annual revenue should still rise 20 per cent to £36m. On a gross margin of 43 per cent this produces gross profit of £15.6m, up from £12.8m in 2020 and £14.3m previously forecast, hence the upgrade in current year Ebitda from £7m to £8.4m and the £1m upgrade in operating profit to £5.6m. On this basis, earnings per share (EPS) rises by 19 per cent to 4.53p. Mr Randall is comfortable with these forecasts. He also notes that proforma net debt of £5m (after accounting for all acquisitions) should unwind to Cenkos’ forecast (£2.1m) by the year-end after factoring in the second half profit contribution and working capital flows. More importantly, the cost savings (staff costs, facilities etc) and revenue synergies (extension of distribution agreement into new territories) from BBI underpin bumper profit growth in 2022, hence why Cenkos believe that BBI can contribute £7m of gross profit (up from £6.1m forecast in 2021) on £12.1m revenue next year. Analysts also believe that Helsin will generate gross profit of £1.6m on revenue of £3m in 2022, too, a sensible prediction given that sales are set to rebound as hospitals restart oncology treatments post pandemic. 2022 earnings growth materially under priced The point is that the contribution from both acquisitions accounts for 40 per cent of Cenkos’ £21m gross profit estimate for 2022 and a third of its £46m revenue estimate. Their contribution de-risks the investment case by diversifying the product offering, while offering a source of profit growth by reinvigorating the brands through self-help measures. Moreover, the acquisitions generate higher gross margins, which is why Cenkos expect Ebitda to rise from £8.5m to £11.95m in 2022. To put that figure into perspective, it’s more or less in line with the upgrade I was looking for in my article last week (‘Exploiting an earnings upgrade opportunity’, 10 August 2021). So, with Ebitda forecast to rise by £3.5m and depreciation charges and amortisation charges only rising by £0.5m, then effectively 85 per cent of next year’s Ebitda growth should be converted into operating profit, hence why Cenkos expect operating profit to rise from £5.6m to £8.5m in 2022 and deliver 38 per cent higher EPS of 6.21p. On this basis, the shares are trading on a miserly, forward PE ratio of 10.5. If anything, the risk to 2022 earnings estimates is skewed to the upside. That’s because Randall confirmed that the company has firepower of £20m plus through Venture’s new bank facility to make further earnings accretive acquisitions. In my view, there has been a massive overreaction to last week’s trading update – 2022 forecasts are in line with the expectations I outlined in last week’s article – and the share price fall is not only overdone, but is likely to prove a cracking buying opportunity. I am certainly not changing my 130p target price. BUY.
farnesbarnes: FarnesBarnes25 Nov '20 - 21:15 - 725 of 1090 Edit 0 0 1 I'm not sure why, but something about VLG suddenly doesn't feel quite right to me. I can't put my finger on it. Within the last month, there's been a 20% fall in 4 days, followed by a near 50% rise the next 4 days, followed by this equity raise and director selling. I hope I'm wrong but something seems fishy. Suffering the same fate as BOTB, albeit, this is the first VLG profit warning. Two more to come.
rivaldo: Looks like a very good acquisition of three oncology brands, two of which VLG already manufacture. Immediately earnings-enhancing given £1.3m historic gross profit for a £4.7m consideration - and that was in the first pandemic year, so there should be a sharp increase in profits from here. Especially with the various synergies and growth/partnering strategies which VLG can bring to the party: Https://
ADVFN Advertorial
Your Recent History
Venture Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210921 23:08:22